FDA authorizes first-time in-house Kovid-19 test that gives users quick results

The Food and Drug Administration has authorized the first Kovid-19 trial designed for users to take and develop at home for results within an hour.

The agency on Tuesday night announced the Emergency Use Authority for the Lusira COVID-19 all-in-one test kit.

The test, which requires a prescription, works in about 30 minutes, the FDA says. People scrub themselves and fill it in a vial, which is then placed in a test unit. The kit is authorized for home use for patients 14 or older. It can also be used for patients of any age in places like hospitals.

FDA Commissioner Stephen M. Hahn has called the kit an important advancement in a statement that helps prevent the spread of the deadly disease.

Lucira Health did not immediately respond to a request for comment about when tests may be available and other details.

Other rapid tests have been granted Emergency Use Authorization by the FDA, but are said to be the first authorized for home use. Some tests have also been authorized for samples to be collected at home, but must then be sent for testing.

Coronavirus cases are on the rise across the country, and health experts warn that there may be significant proliferation in the wake of holidays and cold weather that force more people indoors. Some states or other governments have in recent days increased restrictions to slow the spread of the virus.

As of Tuesday night, more than 11.4 million cases of Kovid-19 have been reported in the United States since the epidemic, with more than 249,000 deaths, according to NBC News calculations.

Leave a Reply

Your email address will not be published. Required fields are marked *